MX2023006898A - Mutaciones en regiones constantes de anticuerpos felinos. - Google Patents

Mutaciones en regiones constantes de anticuerpos felinos.

Info

Publication number
MX2023006898A
MX2023006898A MX2023006898A MX2023006898A MX2023006898A MX 2023006898 A MX2023006898 A MX 2023006898A MX 2023006898 A MX2023006898 A MX 2023006898A MX 2023006898 A MX2023006898 A MX 2023006898A MX 2023006898 A MX2023006898 A MX 2023006898A
Authority
MX
Mexico
Prior art keywords
mutations
constant regions
feline antibody
antibody constant
feline
Prior art date
Application number
MX2023006898A
Other languages
English (en)
Inventor
Sandra Ann Marie Lightle
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2023006898A publication Critical patent/MX2023006898A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos felinos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante de anticuerpo felino para mejorar diversas características.
MX2023006898A 2020-12-18 2021-12-17 Mutaciones en regiones constantes de anticuerpos felinos. MX2023006898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127313P 2020-12-18 2020-12-18
PCT/US2021/064097 WO2022133252A1 (en) 2020-12-18 2021-12-17 Mutations in feline antibody constant regions

Publications (1)

Publication Number Publication Date
MX2023006898A true MX2023006898A (es) 2023-06-26

Family

ID=79730576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006898A MX2023006898A (es) 2020-12-18 2021-12-17 Mutaciones en regiones constantes de anticuerpos felinos.

Country Status (14)

Country Link
EP (1) EP4263596A1 (es)
JP (1) JP2024503212A (es)
KR (1) KR20230121056A (es)
CN (1) CN116547298A (es)
AU (1) AU2021400322A1 (es)
CA (1) CA3202074A1 (es)
CL (1) CL2023001781A1 (es)
CO (1) CO2023007829A2 (es)
EC (1) ECSP23044286A (es)
IL (1) IL303732A (es)
MX (1) MX2023006898A (es)
PE (1) PE20231640A1 (es)
TW (1) TW202233687A (es)
WO (1) WO2022133252A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050491A2 (en) * 2022-09-02 2024-03-07 Zoetis Services Llc Porcine antibody mutants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
BRPI0515230A (pt) 2004-08-19 2008-07-15 Genentech Inc polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2019360271A1 (en) * 2018-10-18 2021-04-29 Elanco Us Inc. Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体

Also Published As

Publication number Publication date
CL2023001781A1 (es) 2023-12-22
CA3202074A1 (en) 2022-06-23
TW202233687A (zh) 2022-09-01
JP2024503212A (ja) 2024-01-25
ECSP23044286A (es) 2023-07-31
AU2021400322A1 (en) 2023-06-22
CN116547298A (zh) 2023-08-04
IL303732A (en) 2023-08-01
PE20231640A1 (es) 2023-10-16
WO2022133252A1 (en) 2022-06-23
KR20230121056A (ko) 2023-08-17
CO2023007829A2 (es) 2023-07-21
EP4263596A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2022012866A (es) Variantes de anticuerpos caninos.
MX2022012793A (es) Variantes de anticuerpos felinos.
ZA202006859B (en) Antibodies specific for gucy2c and uses thereof
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
MX2023005896A (es) Variantes de anticuerpos bovinos.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2019009485A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
CR20230469A (es) Anticuerpos anti-nectina-4 y usos de los mismos
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2023006898A (es) Mutaciones en regiones constantes de anticuerpos felinos.
MX2022008659A (es) Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.
MX2023008785A (es) Mutaciones en regiones constantes de anticuerpos caninos.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
MX2023003624A (es) Variantes de anticuerpos caninos.
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2023003694A (es) Variantes de anticuerpos felinos.
WO2024050493A3 (en) Equine antibody mutants
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.